Novo Nordisk A/S (NYSE:NVO) has signed a drug-discovery and licensing agreement with Orbis Medicines worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are traditionally treated with injections. The deal includes upfront and potential development and commercial milestone payments, tiered royalties on future sales, and a strategic investment by Novo in Orbis. The companies did not disclose the size of the upfront payment, investment, or the breakdown of the $1.4 billion headline value.
The collaboration will use Orbis’ AI-enabled nGen platform to discover orally bioavailable macrocycles, which could potentially reach biological targets that conventional small molecules struggle to address. Orbis said its synthetic macrocycles have achieved up to 18% oral bioavailability in preclinical work. The agreement therefore gives Novo another route to expand its oral cardiometabolic pipeline at a time when oral therapies are becoming an increasingly important part of the obesity market.
Also read: Novo Nordisk Partners with Anthropic to Bring AI Deeper into Drug Discovery
Orbis Technology Could Broaden Novo’s Oral Pipeline
The deal could strengthen Novo Nordisk A/S’s competitive position in oral cardiometabolic medicines beyond its existing Wegovy pill. Reuters reported that Novo expects oral treatments to account for more than one-third of GLP-1-based obesity therapies by 2030, while the U.S. oral obesity market is already becoming highly competitive. As of August, Novo’s Wegovy pill had an estimated 90% share of new U.S. oral weight-loss patients, although Lilly’s Foundayo had recently captured more than 30% of new patients.
Orbis also gives Novo access to a different technology platform rather than relying solely on its existing peptide-based approach. Novo has already invested heavily in oral drug delivery, including its acquisition of Emisphere and its SNAC technology, while recent approvals of oral macrocyclic medicines from Johnson & Johnson and Merck provide evidence that the modality can reach commercial markets.
The financial structure also limits some near-term risk. Much of the $1.4 billion is tied to future milestones rather than an immediately disclosed cash payment, while future royalties could provide Novo with additional products without requiring it to develop every technology entirely internally. This is particularly relevant as Novo seeks to rebuild its pipeline after warning that 2026 sales and operating profit could decline by as much as 13%.
The Partnership Is a Long-Term Bet, Not an Immediate Growth Driver
The $1.4 billion figure should not be treated as $1.4 billion of near-term assets or revenue-generating products. The companies have not disclosed the upfront payment or milestone breakdown, and the collaboration remains at the discovery stage. Consequently, there is no guarantee that the partnership will produce a commercially successful medicine, meaning the immediate earnings and cash-flow contribution for Novo Nordisk A/S is likely to be limited.
There is also a meaningful execution risk around oral macrocycles. Orbis’ reported 18% oral bioavailability was achieved in preclinical studies, not in an approved human medicine. Novo therefore still needs to establish clinical efficacy, safety, manufacturing feasibility and commercial viability for any resulting candidates. Meanwhile, the oral obesity market is already moving quickly: Lilly’s Foundayo has begun taking patients from Novo’s Wegovy pill, showing how rapidly competitive pressure can emerge even in the oral segment.
Market Sentiment:
At the end of Q2 2026, 59 hedge funds tracked by Insider Monkey held stakes in Novo Nordisk A/S, up from 55 in the previous quarter. The stock’s 1.00% short interest suggests relatively limited bearish positioning as the company expands its oral drug pipeline through the Orbis partnership.
Conclusion
The Orbis partnership expands Novo Nordisk A/S’s pipeline into a potentially important next generation of oral cardiometabolic medicines and complements its existing Wegovy pill and SNAC technology. The $1.4 billion headline value, though, is largely contingent on future development and commercial milestones, so it does not immediately change Novo’s earnings or cash flow. The main potential benefit is strategic: securing another oral-drug platform as competition with Lilly intensifies. The key uncertainty is whether Orbis’ preclinical macrocycle technology can translate into effective, commercially viable medicines.
READ NEXT: Aurora Innovation’s Road to Profitability Runs Through Fleet Expansion and Goldman Sachs Looks to Deepen its Footprint in Credit
This article is originally published at Insider Monkey.
